Denosumab for the treatment of osteoporosis.
10.1016/j.afos.2017.01.002
- Author:
Michael R MCCLUNG
1
Author Information
1. Institute of Health and Ageing, Australian Catholic University, Melbourne, Australia.
- Publication Type:Review
- Keywords:
Denosumab;
RANK ligand;
Osteoporosis;
Fracture;
Drug safety
- MeSH:
Asian Continental Ancestry Group;
Denosumab*;
Female;
Humans;
Osteoporosis*;
Osteoporosis, Postmenopausal;
RANK Ligand;
Treatment Outcome
- From:Osteoporosis and Sarcopenia
2017;3(1):8-17
- CountryRepublic of Korea
- Language:English
-
Abstract:
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of denosumab with several thousand patients being followed for up to 10 years. Combined with more than six years of postmarketing experience, these studies provide substantial confidence that denosumab is a convenient and appropriate treatment for patients, including Asians, at high risk for fracture. This review will summarize the clinical development of denosumab and lessons learned since its approval for clinical use in 2010.
